Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602251 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Terbinafine Tablets Under Fed Conditions
A NA study of Onychomycosis, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00602251: Completed NA study of Onychomycosis, sponsored by Roxane Laboratories.
NCT00602251 is a NA study of Onychomycosis that has completed, run by Roxane Laboratories. The registered enrollment target is 30 participants, below the 92-participant average among 11 other Onychomycosis trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00602251, a NA study of Onychomycosis, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
Conditions Studied
Interventions
- DRUG Terbinafine
Study Locations (1)
Missouri
- Gateway Medical Research, Inc. - Saint Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-03 |
| Est. Completion | 2004-04 |
| Phase | NA |
What the finished NCT00602251 record still lists
NCT00602251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 92-participant average among 11 other Onychomycosis trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Onychomycosis appearing as the primary indexed condition, and to 1 intervention - of which Terbinafine is the first listed.
NCT00602251 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00602251 about?
NCT00602251 is a clinical study titled "Bioequivalency Study of Terbinafine Tablets Under Fed Conditions". The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
What is the current status of trial NCT00602251?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2004-03. Estimated completion is 2004-04.
What conditions does trial NCT00602251 study?
This clinical trial studies the following conditions: Onychomycosis.
What interventions are being tested in trial NCT00602251?
The interventions under investigation include: Terbinafine (DRUG).
Who is sponsoring clinical trial NCT00602251?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00602251 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Onychomycosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00602251's enrollment target sits among peer trials
30 6th of 11 higher than 5 of 11 other Onychomycosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Onychomycosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
COMPLETED · NA
-
Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus
COMPLETED · NA
-
Diode Laser Treatment of Onychomycosis
COMPLETED · NA
-
Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions
COMPLETED · NA
-
A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
ACTIVE NOT RECRUITING · Phase 3
-
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia